{
  "abstract": "Recombinant broadly neutralizing antibodies (bNAbs) are promising tools to treat and prevent HIV-1 infection but are associated with manufacturing challenges. To overcome this limitation, we encoded the potent bNAb 1-18-LS on RNA (1-18-LS RibobNAb) for delivery via lipid nanoparticles (LNPs). Indicating high in vivo antibody expression, a 30 ug RNA-LNP intravenous injection resulted in an average peak 1-18-LS RibobNAb serum concentration of 1,061 ug/mL in human neonatal Fc receptor-transgenic mice. Notably, weekly 30 ug RNA-LNP doses maintained higher trough bNAb levels than 500 ug protein injections. Highlighting potent antiviral activity, RNA-LNP-mediated 1-18-LS RibobNAb monotherapy of viremic HIV-1YU2-infected humanized mice resulted in durable HIV-1 suppression without emerging viral escape. Importantly, 1-18-LS RNA-LNP treatment also fully controlled infection after interruption of antiretroviral therapy in humanized mice infected with different patient-derived polyclonal HIV-1 isolates. Our findings provide a proof-of-principle for effective RNA-mediated bNAb immunotherapy of HIV-1 infection.",
  "abstract_shown": true,
  "affiliations": [
    "University Hospital Cologne"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 21,
  "authors": [
    {
      "name": "S. Sayettat"
    },
    {
      "name": "F. Tolksdorf"
    },
    {
      "name": "R. Johannson"
    },
    {
      "name": "J. Nelke"
    },
    {
      "name": "A. Malz"
    },
    {
      "name": "L. Fischer"
    },
    {
      "name": "I. Gerhard"
    },
    {
      "name": "N. Ullrich"
    },
    {
      "name": "U. Ellinghaus"
    },
    {
      "name": "C. R. Stadler"
    },
    {
      "name": "J. P. Bogen"
    },
    {
      "name": "C. Morin"
    },
    {
      "name": "J. Knüfer"
    },
    {
      "name": "R. Stumpf"
    },
    {
      "name": "P. Schommers"
    },
    {
      "name": "U. Sahin"
    },
    {
      "name": "M. S. Seaman"
    },
    {
      "name": "S. Kratochvil"
    },
    {
      "name": "F. Klein"
    },
    {
      "name": "V. Le Douce"
    },
    {
      "affs": [
        0
      ],
      "name": "H. Gruell"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4a6v4nv1rbxca.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.17.752120",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752120v1.full",
  "id": "4a6v4nv1rbxca",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752120v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "immunology"
    ],
    [
      "openalex",
      "2406|HIV Research and Treatment"
    ]
  ],
  "openalex": "W7213764045",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752120v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-17",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4a6v4nv1rbxca.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:23:19Z",
      "native_id": "10.64898/2026.09.17.752120",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.09.17.752120v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "biorxiv:immunology",
      "subfield": "immunology"
    }
  ],
  "title": "Durable suppression of viremia by lipid nanoparticle-formulated RNA encoding for a highly potent HIV-1 neutralizing antibody",
  "title_text": "Durable suppression of viremia by lipid nanoparticle-formulated RNA encoding for a highly potent HIV-1 neutralizing antibody",
  "type": "preprint",
  "updated_at": "2026-10-30T12:23:19Z",
  "url": "https://research.draconitic.com/paper/4a6v4nv1rbxca",
  "venue": "bioRxiv",
  "versions": []
}